Next Generation Of Hormone Therapies


We are dedicated to discovering, acquiring, and
developing novel compounds to treat hormone responsive cancers

Blue gloved hands holding open a drug capsule with colorful balls inside.jpg

Context approach

Sigma1 Icon

Company Builders 

Discovering, acquiring, and developing novel compounds to treat hormone-responsive cancers.

Biomarkers Icon

HR+ Cancers

Hormone receptor positive (HR+) cancers, including, prostate, breast, and gastrointestinal result in almost 200,000 deaths per year in the United States.

Therapeutic Focus Icon

Apristor (Onapristone XR)

Apristor is our most advanced program and is a selective anti-progestin for metastatic breast and ovarian cancers.

our team

We are building Context Therapeutics to become a global company that will discover, develop and market groundbreaking cancer treatments to patients around the world, eliminating the fear that comes with a cancer diagnosis.

+ meet the team

Our Partners

The best ideas are often developed through external collaboration. To facilitate collaboration, our Team makes available to academic labs and private research institutes our "Toolkits" that contain proprietary compounds, screening assays, reagents, and tools. The goal of these relationships is to expand our current knowledge of Context's Core Indications and to find new uses of our compounds to treat diseases of significant unmet medical need.

Young scientist mixing drugs for drug discovery trials in colorful lab